查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1963819

即时血糖值监测市场－全球产业规模、份额、趋势、机会、预测：依产品类型、地区和竞争格局划分，2021-2031年

Point-of-Care Glucose Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球即时血糖监测市场预计将从 2025 年的 36.2 亿美元成长到 2031 年的 46.8 亿美元，复合年增长率为 4.37%。

此市场领域涵盖可在医院、诊所和居家医疗等临床环境中提供即时血糖分析的诊断设备和耗材。推动该领域成长的主要因素是生活方式相关代谢疾病的日益普遍以及全球人口的快速老化，这需要频繁的健康监测。与技术趋势不同，这些根本驱动因素代表了结构性的人口和流行病学变化，需要分散式快速诊断解决方案来减轻中心检查室基础设施的负担。

市场概览
预测期 2027-2031
市场规模：2025年 36.2亿美元
市场规模：2031年 46.8亿美元
复合年增长率：2026-2031年 4.37%
成长最快的细分市场 AccuChek Inform II
最大的市场 北美洲

然而，阻碍市场扩张的一大障碍是严格的法规结构，该框架界定了设备的准确性和性能标准。这为製造商设定了很高的进入门槛。这些严格的合规要求可能导致产品核可延迟和研发成本增加，从而限制新解决方案进入消费者市场的速度。根据国际糖尿病联盟 (IDF) 估计，到 2024 年，全球约有 5.89 亿成年人将患有糖尿病。如此巨大的疾病负担凸显了开发便捷且合规的检测方法的迫切需求，儘管监管压力带来了许多操作上的困难。

市场驱动因素

持续血糖监测系统的技术进步正在从根本上改变全球照护现场血糖监测市场，以即时、基于感测器的追踪取代间歇性毛细血管血检测。这些创新显着提高了患者的依从性和临床疗效，并透过预测性警报、延长感测器佩戴时间和无缝智慧型手机整合等功能，大幅降低了日常管理的侵入性。这种技术变革的商业性影响在基于感测器的平台快速成长中显而易见。根据雅培公司2024年10月发布的2024年第三季财报显示，其FreeStyle Libre持续血糖监测系统的销售额达到16亿美元，显示市场对这些先进诊断技术有着大规模的需求。这种快速成长凸显了用户友善创新在推动照护现场领域扩张方面发挥的关键作用。

同时，随着医疗保健系统将慢性病管理分散化，减轻医院负担，居家自我管理解决方案的采用率不断提高，市场进入也不断扩大。这种结构性转变很大程度上是由于应对疾病日益增长的经济影响的经济需求而加速的，从而推动了经济高效、患者可自行操作的诊断设备的普及。这种以患者为中心的模式的可行性体现在领先的居家医疗设备供应商的表现上。根据Dexcom于2024年10月发布的2024年第三季财报，季度营收达到9.942亿美元，主要得益于自我管理生物感测器的普及。需要频繁监测的患者群体不断成长，进一步推动了这项转变。世界卫生组织（WHO）于2024年11月发布的数据显示，全球糖尿病成人患者人数已超过8亿，这持续推高了对个人诊断设备的需求，并强化了医疗保健分散化的市场趋势。

市场挑战

医疗设备准确性和性能标准的严格法规结构是全球照护现场血糖检测市场成长的主要障碍。製造商必须遵守复杂的合规程序并进行大规模临床试验，以满足严格的安全标准。这项严苛的流程显着提高了进入门槛，推高了研发成本，并延长了新产品的商业化时间。这些营运障碍阻碍了中小型创新企业进入该领域，减缓了检测解决方案向消费者交付的速度。

因此，市场扩张速度难以满足全球日益增长的分散式监测需求。对便利诊断工具的迫切需求与缓慢的监管核准之间存在差距，限制了经济高效方案的普及。世界卫生组织（世卫组织）预测，到2024年，全球糖尿病患者人数将超过8亿人。如此庞大的疾病负担凸显了监管审批延迟阻碍市场发展的巨大缺口，也使得市场未能充分利用日益增长的、需要即时血糖分析的患者群体。

市场趋势

人工智慧 (AI) 和机器学习在预测分析领域的融合，正将血糖监测从被动应对转变为主动预防。演算法透过分析过往模式预测血糖波动，从而为决策支援系统提供关键的预防性干预措施。这项功能能够识别不利事件，并在其发生前就识别出来，从而提升临床效用，并在精准医疗领域日益受到重视。根据发表于 2024 年 5 月 JMIR Medical Informatics 期刊的一篇题为「基于连续血糖监测的低血糖预测深度学习模型的泛化」的论文，基于长期记忆网络 (LSTM) 的深度学习模型在预测严重低血糖方面达到了 96.40% 的曲线下面积(AUC)。如此高的预测准确率使製造商能够实现可靠的自动警报，从而增强用户对下一代平台的信心。

无需处方笺的连续血糖生物感测器的出现，正从根本上改变着血糖监测的可及性，因为它将技术与处方要求脱钩。这一趋势的目标族群是那些透过改善生活方式而非依赖胰岛素来管理代谢健康的庞大群体。透过消除监管障碍，製造商正将目标市场从核心的1型糖尿病患者群体扩展到糖尿病前期患者和健康管理用户。根据Dekkom公司2024年3月发布的新闻稿《Dekkom Stero获FDA核准成为首个商业化血糖生物感测器》，美国约有2,500万2型糖尿病患者不使用胰岛素，他们可以从这项技术中获益。这种透过处方笺即可使用的淘汰实现的扩张，将有助于早期疗育，并显着提升该领域的商业性规模。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球即时血糖值监测市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 产品类型（AccuChek Aviva血糖机、OneTouch Verio Flex、i-STAT、拜耳Contour血糖监测系统、FreeStyle Lite、True Matrix、AccuChek InForm II、StatStrip、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美即时血糖值监测市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲即时血糖值监测市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区即时血糖值监测市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲即时血糖值监测市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲即时血糖值监测市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章 全球即时血糖值监测市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories Inc.
  • Nipro Corporation
  • Lifescan, Inc.
  • Nova Biomedical Corporation
  • ACON Laboratories Inc.
  • Trividia Health, Inc.
  • Prodigy Diabetes Care, LLC
  • Ascensia Diabetes Care Holdings AG
  • EKF Diagnostics Holdings PLC

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 23979

The Global Point-of-Care Glucose Testing Market is projected to expand from USD 3.62 Billion in 2025 to USD 4.68 Billion by 2031, reflecting a compound annual growth rate of 4.37%. This market sector comprises diagnostic instruments and consumables designed to deliver immediate blood sugar analysis at the point of care, encompassing hospitals, clinics, and home healthcare settings. Growth is primarily underpinned by the escalating prevalence of lifestyle-induced metabolic disorders and a rapidly aging global population that requires frequent health monitoring. These foundational drivers are distinct from technological trends, representing structural demographic and epidemiological shifts that necessitate decentralized and rapid diagnostic solutions to alleviate the burden on central laboratory infrastructure.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.62 Billion
Market Size 2031USD 4.68 Billion
CAGR 2026-20314.37%
Fastest Growing SegmentAccu-Chek Inform II
Largest MarketNorth America

However, a significant challenge impeding broader market expansion is the stringent regulatory framework governing device accuracy and performance standards, which creates high barriers to entry for manufacturers. These rigorous compliance requirements can delay product approvals and increase development costs, thereby limiting the speed at which new solutions reach the consumer. According to the 'International Diabetes Federation', in '2024', approximately 589 million adults worldwide were estimated to be living with diabetes. This substantial disease burden underscores the critical necessity for accessible and compliant testing modalities, despite the operational difficulties imposed by regulatory pressures.

Market Driver

Technological advancements in Continuous Glucose Monitoring Systems are fundamentally reshaping the Global Point-of-Care Glucose Testing Market by replacing episodic capillary blood checks with real-time, sensor-based tracking. These innovations significantly enhance patient compliance and clinical outcomes through features like predictive alerts, extended sensor wear-time, and seamless smartphone integration, which collectively reduce the invasiveness of daily management. The commercial impact of this technological shift is evident in the rapid growth of sensor-based platforms; according to Abbott, October 2024, in the 'Third Quarter 2024 Financial Results', sales of the FreeStyle Libre continuous glucose monitoring system reached $1.6 billion, demonstrating the substantial market appetite for these advanced diagnostic technologies. This surge underscores the critical role of user-friendly innovation in driving the expansion of the point-of-care landscape.

Concurrently, the rising adoption of home-based self-monitoring solutions is broadening market access as healthcare systems decentralize chronic disease management to alleviate hospital burdens. This structural shift is heavily accelerated by the economic necessity of managing the condition's escalating financial impact, incentivizing the widespread deployment of cost-effective, patient-operated testing devices. The viability of this patient-centric model is reflected in the performance of major home-care device providers; according to Dexcom, October 2024, in the 'Third Quarter 2024 Financial Results', quarterly revenue reached $994.2 million, driven largely by the uptake of self-monitoring biosensors. This transition is further supported by the expanding patient pool requiring frequent monitoring; according to the World Health Organization, in November 2024, the number of adults living with diabetes worldwide surpassed 800 million, creating a sustained demand for personal diagnostic instruments and reinforcing the market's trajectory towards decentralized care.

Market Challenge

The stringent regulatory framework governing device accuracy and performance standards stands as a primary obstacle hampering the growth of the Global Point-of-Care Glucose Testing Market. Manufacturers must navigate complex compliance protocols and conduct extensive clinical trials to meet rigorous safety benchmarks. This demanding process creates substantial barriers to entry, inflating development costs and extending the timeline required to bring new products to commercial realization. These operational hurdles discourage smaller innovators from entering the sector and slow the pace at which testing solutions become available to consumers.

Consequently, the market struggles to scale rapidly enough to address the escalating global demand for decentralized monitoring. The disconnect between the urgent need for accessible diagnostic tools and the slow rate of regulatory approval restricts the availability of cost-effective options. According to the 'World Health Organization', in '2024', the number of adults living with diabetes worldwide surpassed 800 million. This magnitude of disease burden highlights the critical gap where regulatory delays prevent the market from fully capitalizing on the expanding patient base that requires immediate glucose analysis.

Market Trends

The integration of Artificial Intelligence and Machine Learning for predictive analytics is moving glucose monitoring from reactive to proactive. Algorithms now analyze historical patterns to forecast fluctuations, enabling preventative interventions critical for decision support systems. This capability enhances clinical utility by identifying adverse events before they occur, a feature increasingly demanded in precision medicine. According to JMIR Medical Informatics, May 2024, in the study 'Generalization of a Deep Learning Model for Continuous Glucose Monitoring-Based Hypoglycemia Prediction', a deep learning model based on long short-term memory networks achieved an Area Under the Curve of 96.40% for predicting severe hypoglycemia. This predictive accuracy allows manufacturers to deploy reliable automated alerts, increasing user trust in next-generation platforms.

The emergence of Over-the-Counter Continuous Glucose Biosensors is structurally shifting accessibility by decoupling technology from prescription requirements. This trend targets the massive demographic managing metabolic health through lifestyle modifications rather than insulin. By removing regulatory friction, manufacturers are expanding their addressable market beyond the core Type 1 diabetes population to include pre-diabetics and wellness users. According to Dexcom, March 2024, in the press release 'Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter', there are approximately 25 million people in the U.S. living with Type 2 diabetes who do not use insulin and who can benefit from this technology. This non-prescription expansion facilitates earlier intervention, significantly broadening the sector's commercial scope.

Key Market Players

  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories Inc.
  • Nipro Corporation
  • Lifescan, Inc.
  • Nova Biomedical Corporation
  • ACON Laboratories Inc.
  • Trividia Health, Inc.
  • Prodigy Diabetes Care, LLC
  • Ascensia Diabetes Care Holdings AG
  • EKF Diagnostics Holdings PLC

Report Scope

In this report, the Global Point-of-Care Glucose Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Point-of-Care Glucose Testing Market, By Product Type

  • Accu Check Aviva Meter
  • Onetouch Verio Flex
  • i-STAT
  • Bayer CONTOUR Blood Glucose Monitoring System
  • Freestyle Lite
  • True Metrix
  • Accu-Chek Inform II
  • StatStrip
  • Others

Point-of-Care Glucose Testing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Point-of-Care Glucose Testing Market.

Available Customizations:

Global Point-of-Care Glucose Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Point-of-Care Glucose Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Accu Check Aviva Meter, Onetouch Verio Flex, i-STAT, Bayer CONTOUR Blood Glucose Monitoring System, Freestyle Lite, True Metrix, Accu-Chek Inform II, StatStrip, Others)
    • 5.2.2. By Region
    • 5.2.3. By Company (2025)
  • 5.3. Market Map

6. North America Point-of-Care Glucose Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Point-of-Care Glucose Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
    • 6.3.2. Canada Point-of-Care Glucose Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
    • 6.3.3. Mexico Point-of-Care Glucose Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type

7. Europe Point-of-Care Glucose Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Point-of-Care Glucose Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
    • 7.3.2. France Point-of-Care Glucose Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
    • 7.3.3. United Kingdom Point-of-Care Glucose Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
    • 7.3.4. Italy Point-of-Care Glucose Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
    • 7.3.5. Spain Point-of-Care Glucose Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type

8. Asia Pacific Point-of-Care Glucose Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Point-of-Care Glucose Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
    • 8.3.2. India Point-of-Care Glucose Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
    • 8.3.3. Japan Point-of-Care Glucose Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
    • 8.3.4. South Korea Point-of-Care Glucose Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
    • 8.3.5. Australia Point-of-Care Glucose Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type

9. Middle East & Africa Point-of-Care Glucose Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Point-of-Care Glucose Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
    • 9.3.2. UAE Point-of-Care Glucose Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
    • 9.3.3. South Africa Point-of-Care Glucose Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type

10. South America Point-of-Care Glucose Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Point-of-Care Glucose Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
    • 10.3.2. Colombia Point-of-Care Glucose Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
    • 10.3.3. Argentina Point-of-Care Glucose Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Point-of-Care Glucose Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F. Hoffmann-La Roche Ltd
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Abbott Laboratories Inc.
  • 15.3. Nipro Corporation
  • 15.4. Lifescan, Inc.
  • 15.5. Nova Biomedical Corporation
  • 15.6. ACON Laboratories Inc.
  • 15.7. Trividia Health, Inc.
  • 15.8. Prodigy Diabetes Care, LLC
  • 15.9. Ascensia Diabetes Care Holdings AG
  • 15.10. EKF Diagnostics Holdings PLC

16. Strategic Recommendations

17. About Us & Disclaimer